Sanofi Genzyme announced that positive new brain volume data from an ongoing clinical study of Lemtrada (alemtuzumab) was presented at the 68th American Academy of Neurology (AAN) Annual Meeting. In addition, new data from an exploratory study will be shared, which demonstrate the impact of Lemtrada on retinal nerve fibers.
“The Lemtrada data being presented at AAN from the ongoing extension study demonstrating slowed brain volume loss over three years are consistent with sustained effects seen in prior clinical, imaging and atrophy analyses,” said Dr. Anthony Traboulsee, Associate Professor of Neurology and Medical Director of the UBC Hospital MS Clinic of Vancouver Coastal Health. “In addition, given the critical importance of neuroprotection in the treatment of MS, the retinal nerve fiber data are also exciting and support further investigation.”
Lemtrada Investigational Brain Volume Data: Relapsing-remitting multiple sclerosis (RRMS) patients treated with interferon beta-1a in CARE-MS I and II for two years who switched to Lemtrada in the extension study experienced a reduced rate of brain volume loss over the next three years.
Lemtrada Investigational Retinal Data: A measurable improvement in retinal nerve fiber layer (RNFL) thickness was seen in 26 Lemtrada-treated RRMS patients. The observed thickening of retinal fibers may reflect protection of retinal axons in these patients.
Do you take Lemtrada?
Above image from www.ineverything.ca